aTyr Pharma, Inc.

NasdaqCM:ATYR 주식 보고서

시가총액: US$261.9m

aTyr Pharma 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Sanjay Shukla

최고 경영자

US$1.3m

총 보상

CEO 급여 비율43.2%
CEO 임기7yrs
CEO 소유권0.2%
경영진 평균 재임 기간5.9yrs
이사회 평균 재임 기간15.1yrs

최근 관리 업데이트

Recent updates

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Sep 09

We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

Jul 13
We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Feb 03
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Oct 04
Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

May 06
Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Jan 04
We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

Sep 29

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

Sep 13

aTyr Pharma gains with FDA Fast Track status for lead asset

Aug 11

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

May 10
We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Jan 24
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Dec 28

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Sep 24

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Sep 23
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

May 22
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 25
aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

Feb 09
Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan

Jan 14

ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study

Jan 04

aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study

Dec 21

aTyr Pharma (LIFE) Investor Presentation - Slideshow

Oct 31

CEO 보상 분석

Sanjay Shukla 의 보수는 aTyr Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$54m

Dec 31 2023US$1mUS$561k

-US$50m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$2mUS$561k

-US$45m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$41m

Mar 31 2022n/an/a

-US$39m

Dec 31 2021US$2mUS$510k

-US$34m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$29m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020US$1mUS$470k

-US$16m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$664kUS$450k

-US$24m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$25m

Mar 31 2019n/an/a

-US$30m

Dec 31 2018US$1mUS$450k

-US$35m

Sep 30 2018n/an/a

-US$40m

Jun 30 2018n/an/a

-US$44m

Mar 31 2018n/an/a

-US$45m

Dec 31 2017US$2mUS$403k

-US$48m

보상 대 시장: Sanjay 의 총 보상 ($USD 1.30M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 1.46M ).

보상과 수익: Sanjay 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Sanjay Shukla (52 yo)

7yrs

테뉴어

US$1,300,525

보상

Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...

리더십 팀

이름위치테뉴어보상소유권
Sanjay Shukla
President7yrsUS$1.30m0.16%
$ 426.0k
Jill Broadfoot
Chief Financial Officer6.3yrsUS$677.84k0.025%
$ 65.0k
Nancy E. Krueger
General Counsel & Corporate Secretary10.1yrsUS$651.28k0.027%
$ 69.5k
Xiang-Lei Yang
Founderno data데이터 없음데이터 없음
Jayant Aphale
Vice President of Technical Operationsless than a year데이터 없음데이터 없음
Ashlee Dunston
Director of Investor Relations & Corporate Communicationsno data데이터 없음데이터 없음
Peter Villiger
Vice President of Corporate Development4.8yrs데이터 없음데이터 없음
Danielle Campbell
VP of Human Resource2.9yrs데이터 없음데이터 없음
Leslie Nangle
Vice President of Researchno data데이터 없음데이터 없음
Ying Buechler
Executive Director of Biologics Development & Manufacturingno data데이터 없음데이터 없음
David King
Scientific Consultant5.9yrsUS$717.31k데이터 없음

5.9yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: ATYR 의 관리팀은 노련하고 경험 (평균 재직 기간 5.9 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Sanjay Shukla
President7yrsUS$1.30m0.16%
$ 426.0k
John Clarke
Independent Director19.2yrsUS$120.84k0.024%
$ 61.8k
Paul Schimmel
Independent Director19.2yrsUS$61.20k1.31%
$ 3.4m
Floyd Bloom
Member of Scientific Advisory Board15.1yrs데이터 없음데이터 없음
Bruce Beutler
Member of Scientific Advisory Board15.3yrs데이터 없음데이터 없음
Benjamin Cravatt
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Timothy Coughlin
Independent Chairman of the Board7.6yrsUS$92.20k0.067%
$ 174.7k
Osamu Nureki
Member of Scientific Advisory Board15.2yrs데이터 없음데이터 없음
Susan Ackerman
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Wing Wong
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Nancy Ip
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Jane Gross
Independent Director5.3yrsUS$68.88k0.0072%
$ 18.7k

15.1yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: ATYR 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 15.1 년).